IL229697A0 - Methods for repairing tissue damage using protease-resistant mutants of stromal cells derived from factor 1 - Google Patents

Methods for repairing tissue damage using protease-resistant mutants of stromal cells derived from factor 1

Info

Publication number
IL229697A0
IL229697A0 IL229697A IL22969713A IL229697A0 IL 229697 A0 IL229697 A0 IL 229697A0 IL 229697 A IL229697 A IL 229697A IL 22969713 A IL22969713 A IL 22969713A IL 229697 A0 IL229697 A0 IL 229697A0
Authority
IL
Israel
Prior art keywords
protease
methods
tissue damage
cell derived
stromal cell
Prior art date
Application number
IL229697A
Other languages
English (en)
Hebrew (he)
Original Assignee
Provasculon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Provasculon Inc filed Critical Provasculon Inc
Publication of IL229697A0 publication Critical patent/IL229697A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/522—Alpha-chemokines, e.g. NAP-2, ENA-78, GRO-alpha/MGSA/NAP-3, GRO-beta/MIP-2alpha, GRO-gamma/MIP-2beta, IP-10, GCP-2, MIG, PBSF, PF-4, KC
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
IL229697A 2011-06-07 2013-11-28 Methods for repairing tissue damage using protease-resistant mutants of stromal cells derived from factor 1 IL229697A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161494079P 2011-06-07 2011-06-07
PCT/US2012/041054 WO2012170495A1 (en) 2011-06-07 2012-06-06 Methods for repairing tissue damage using protease-resistant mutants of stromal cell derived factor-1

Publications (1)

Publication Number Publication Date
IL229697A0 true IL229697A0 (en) 2014-01-30

Family

ID=47296407

Family Applications (1)

Application Number Title Priority Date Filing Date
IL229697A IL229697A0 (en) 2011-06-07 2013-11-28 Methods for repairing tissue damage using protease-resistant mutants of stromal cells derived from factor 1

Country Status (8)

Country Link
US (1) US10662234B2 (enExample)
EP (1) EP2717894B1 (enExample)
JP (2) JP6145089B2 (enExample)
CN (1) CN103747795A (enExample)
AU (2) AU2012268078B2 (enExample)
CA (1) CA2838155C (enExample)
IL (1) IL229697A0 (enExample)
WO (1) WO2012170495A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011106234A1 (en) 2010-02-25 2011-09-01 Provasculon, Inc. Protease-resistant mutants of stromal cell derived factor-1 in the repair of tissue damage
JP6145089B2 (ja) 2011-06-07 2017-06-07 メソブラスト インターナショナル エスエイアールエル ストロマ細胞由来因子−１のプロテアーゼ耐性変異体を用いた、組織損傷を修復するための方法
AU2014362198A1 (en) * 2013-12-13 2016-07-07 Mesoblast International Sarl Methods for repairing tissue damage using protease-resistant mutants of stromal cell derived factor-1
ES2822924T3 (es) * 2014-09-26 2021-05-05 Helixmith Co Ltd Composición para prevenir o tratar una enfermedad arterial periférica utilizando el factor de crecimiento de hepatocitos y el factor 1a derivado de células del estroma
CN114366806A (zh) * 2021-12-16 2022-04-19 天津市泌尿外科研究所 一种纳米黑磷负载sdf-1的纳米药物复合体及其制备方法和应用
CN122297638A (zh) * 2026-06-02 2026-06-30 中国人民解放军陆军特色医学中心 多肽srd在制备治疗急性肺损伤药物中的应用

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5171680A (en) 1988-06-14 1992-12-15 Chiron Corporation Superoxide dismutase analogs having novel binding properties
DK0608235T4 (da) 1991-11-13 2005-05-30 A C Thrombosis And Coagulati T Fremgangsmåde til diagnose af blodkoagulationssygdomme
US5670483A (en) 1992-12-28 1997-09-23 Massachusetts Insititute Of Technology Stable macroscopic membranes formed by self-assembly of amphiphilic peptides and uses therefor
JP3367581B2 (ja) 1993-10-14 2003-01-14 小野薬品工業株式会社 新規なポリペプチド、その製造方法、そのポリペプチドをコードするｄｎａ、そのｄｎａからなるベクター、そのベクターで形質転換された宿主細胞
US6852508B1 (en) 1997-02-28 2005-02-08 Genetics Institute, Llc Chemokine with amino-terminal modifications
US6100387A (en) 1997-02-28 2000-08-08 Genetics Institute, Inc. Chimeric polypeptides containing chemokine domains
US6214540B1 (en) 1997-03-26 2001-04-10 University Of Maryland Biotechnology Institute Chemokines that inhibit immunodeficiency virus infection and methods based thereon
CA2245224A1 (en) 1998-08-14 2000-02-14 Jiang-Hong Giong Chemokine receptor antagonists and chemotherapeutics
DE69914463T2 (de) 1998-03-13 2004-11-11 The University Of British Columbia, Vancouver Therapeutische chemokine rezeptor antagonisten
CA2305787A1 (en) 2000-05-09 2001-11-09 The University Of British Columbia Cxcr4 antagonist treatment of hematopoietic cells
US20020107195A1 (en) 1998-07-21 2002-08-08 Smithkline Beecham Corporation Method for inducing chemotaxis in endothelial cells by administering stromal cell derived factor-1alpha
US6440934B1 (en) * 1998-10-13 2002-08-27 Chiron Corporation Angiogenically effective unit dose of FGF-2 and method of use
AU766190B2 (en) * 1998-10-16 2003-10-09 Biogen Idec Ma Inc. Interferon-beta fusion proteins and uses
US6221856B1 (en) 1999-02-03 2001-04-24 Inologic, Inc. Inositol derivatives for inhibiting superoxide anion production
AU2003901668A0 (en) 2003-03-28 2003-05-01 Medvet Science Pty. Ltd. Non-haemopoietic precursor cells
CA2335109A1 (en) 2000-04-12 2001-10-12 Chemokine Therapeutics Corporation Cxcr4 agonist treatment of hematopoietic cells
US7368425B2 (en) 2006-03-24 2008-05-06 Chemokine Therapeutics Corp. Cyclic peptides for modulating growth of neo-vessels and their use in therapeutic angiogenesis
US20050059584A1 (en) 2002-08-16 2005-03-17 Ahmed Merzouk Novel chemokine mimetics synthesis and their use
US7378098B2 (en) 2000-04-12 2008-05-27 The University Of British Columbia CXC chemokine receptor 4 agonist peptides
DE10027383A1 (de) 2000-06-02 2001-12-20 Rhein Biotech Proz & Prod Gmbh Nukleinsäure-Molekül umfassend eine für ein Chemokin, einen Neuropeptid-Präkursor oder mindestens ein Neuropeptid kodierende Nukleinsäuresequenz
EP2324839B1 (en) 2000-06-05 2017-08-09 The Trustees of Columbia University in the City of New York Granulocyte-colony-stimulating-factor (g-csf) for use in the treatment of myocardial infarct
US7547674B2 (en) 2001-06-06 2009-06-16 New York Medical College Methods and compositions for the repair and/or regeneration of damaged myocardium
US20020094327A1 (en) 2000-11-05 2002-07-18 Petersen Bryon E. Targeting pluripotent stem cells to tissues
EP1335744A2 (en) 2000-11-09 2003-08-20 Genetics Institute, LLC Sdf-1 beta expressing tumor cells as tumor vaccines
US20020111290A1 (en) 2000-12-01 2002-08-15 Bernhard Homey Uses of mammalian genes and related reagents
US20020156023A1 (en) 2000-12-06 2002-10-24 Tularik Inc. Lometrexol combination therapy
AU2002348241A1 (en) 2001-11-24 2003-06-10 Image Analysis, Inc. Automatic detection and quantification of coronary and aortic calcium
US20030199464A1 (en) 2002-04-23 2003-10-23 Silviu Itescu Regeneration of endogenous myocardial tissue by induction of neovascularization
WO2003094950A2 (en) 2002-05-10 2003-11-20 Ipf Pharmaceuticals Gmbh A method of inhibiting the emigration of cells from the intravascular compartment into tissues
US7485141B2 (en) 2002-05-10 2009-02-03 Cordis Corporation Method of placing a tubular membrane on a structural frame
US20050065064A1 (en) 2002-08-09 2005-03-24 Elias Lolis Identification of allosteric peptide agonists of CXCR4
US20050271639A1 (en) 2002-08-22 2005-12-08 Penn Marc S Genetically engineered cells for therapeutic applications
US20040037811A1 (en) 2002-08-22 2004-02-26 The Cleveland Clinic Foundation Stromal cell-derived factor-1 mediates stem cell homing and tissue regeneration in ischemic cardiomyopathy
JP2006502142A (ja) 2002-08-23 2006-01-19 ブリストル−マイヤーズ　スクイブ　カンパニー 虚血性損傷を減少させる方法
US20070060512A1 (en) 2003-03-04 2007-03-15 Homayoun Sadeghi Dipeptidyl-peptidase protected protein
WO2004094465A2 (en) 2003-04-23 2004-11-04 The Board Of Trustees Of The University Of Illinois Office Of Technology Management University Of Illinois At Urbana-Champaign Synthetic molecules that mimic chemokines
US7776564B2 (en) 2004-04-30 2010-08-17 Five Prime Therapeutics, Inc. Stromal cell-derived factor-1 polypeptides, polynucleotides, modulators thereof and methods of use
WO2006030887A1 (ja) 2004-09-17 2006-03-23 Cellgentech, Inc. 外用皮膚潰瘍治療剤
CN101103101B (zh) 2004-09-24 2012-10-10 成血管细胞系统公司 增强间充质前体细胞（mpc）的增生和/或存活的方法
US7399831B2 (en) 2004-10-25 2008-07-15 The Brigham And Women's Hospital, Inc. Targeted delivery of biological factors using self-assembling peptide nanofibers
US20060110374A1 (en) 2004-11-24 2006-05-25 Dudy Czeiger Method to accelerate stem cell recruitment and homing
AU2005323062A1 (en) 2005-01-04 2006-07-13 The Brigham And Women's Hospital, Inc. Sustained delivery of PDGF using self-assembling peptide nanofibers
WO2006074464A2 (en) 2005-01-10 2006-07-13 Mayo Foundation For Medical Education And Research Modulating toll-like receptor activity
KR20100102750A (ko) 2005-04-25 2010-09-24 메사추세츠 인스티튜트 오브 테크놀로지 지혈 및 다른 생리학적 활성을 촉진하기 위한 조성물 및 방법
WO2007051785A2 (en) * 2005-10-31 2007-05-10 Laboratoire Serono S.A. Use of sdf-1 for the treatment and/or prevention of neurological diseases
WO2007079460A2 (en) 2006-01-04 2007-07-12 Chemokine Therapeutics Corporation Design of cxc chemokine analogs for the treatment of human diseases
US7776816B2 (en) 2006-01-20 2010-08-17 Board Of Regents, The University Of Texas System Preserving hypoxic tissue
JP5244785B2 (ja) 2006-08-11 2013-07-24 小野薬品工業株式会社 ストローマ由来因子−１（ｓｄｆ−１）に対するモノクローナル抗体
US7696309B2 (en) 2006-10-23 2010-04-13 The Brigham And Women's Hospital, Inc. Protease resistant mutants of stromal cell derived factor-1 in the repair of tissue damage
US20080194478A1 (en) 2007-02-09 2008-08-14 Gene Signal International Sa Wound healing agent and composition
ES2520044T3 (es) 2007-03-30 2014-11-11 The Cleveland Clinic Foundation SDF-1 para su uso en el tratamiento de trastornos vasculares periféricos isquémicos
ES2325715B1 (es) 2007-08-03 2010-06-17 Genetrix, S.L. Poblacion de celulas madre adultas derivadas de tejido adiposo cardiaco y su uso en regeneracion cardiaca.
US8414924B2 (en) 2007-10-10 2013-04-09 Kyoto University Preparation for treating heart disease used in cell therapy
ATE543507T1 (de) * 2007-11-07 2012-02-15 Ono Pharmaceutical Co Sdf-1 enthaltende zusammensetzung mit anhaltender freisetzung
EP2100954A1 (en) 2008-03-10 2009-09-16 Assistance Publique - Hopitaux de Paris Method for generating primate cardiac progenitor cells for clinical use from primate embryonic stem cells, and their applications
WO2010024300A1 (ja) 2008-08-26 2010-03-04 国立大学法人 北海道大学 骨充填型軟骨組織再生誘導剤
KR20120047214A (ko) 2009-05-20 2012-05-11 보드 오브 리전츠 더 유니버시티 오브 텍사스 시스템 심근경색 후 리모델링 및 심부전에 관련된 마이크로―ｒｎａ의 확인
WO2010138180A2 (en) * 2009-05-26 2010-12-02 The University Of Vermont And State Agriculture College Compositions and methods for cardiac tissue repair
WO2011106234A1 (en) * 2010-02-25 2011-09-01 Provasculon, Inc. Protease-resistant mutants of stromal cell derived factor-1 in the repair of tissue damage
WO2012027170A1 (en) * 2010-08-23 2012-03-01 Provasculon, Inc. Methods for repairing tissue damage using protease-resistant mutants of stromal cell derived factor-1
WO2012026041A1 (ja) * 2010-08-27 2012-03-01 富士通株式会社 並列計算機、並列計算機のジョブ情報取得プログラム、並列計算機のジョブ情報取得方法、計算装置及び計算管理装置
JP6145089B2 (ja) 2011-06-07 2017-06-07 メソブラスト インターナショナル エスエイアールエル ストロマ細胞由来因子−１のプロテアーゼ耐性変異体を用いた、組織損傷を修復するための方法
AU2014362198A1 (en) 2013-12-13 2016-07-07 Mesoblast International Sarl Methods for repairing tissue damage using protease-resistant mutants of stromal cell derived factor-1

Also Published As

Publication number Publication date
EP2717894A1 (en) 2014-04-16
CA2838155A1 (en) 2012-12-13
AU2012268078B2 (en) 2017-06-01
US20140199304A1 (en) 2014-07-17
WO2012170495A1 (en) 2012-12-13
JP6145089B2 (ja) 2017-06-07
CA2838155C (en) 2021-10-19
US10662234B2 (en) 2020-05-26
AU2017213440A1 (en) 2017-08-24
JP2014519514A (ja) 2014-08-14
EP2717894B1 (en) 2018-01-24
CN103747795A (zh) 2014-04-23
JP2017114867A (ja) 2017-06-29
AU2012268078A1 (en) 2013-12-19
EP2717894A4 (en) 2015-02-25

Similar Documents

Publication Publication Date Title
KR101155817B9 (ko) 조직거상용 이식물
PL2694642T3 (pl) Sposób odmładzania komórek
EP2757999A4 (en) IMPLANT OF HARD FABRIC
ZA201306312B (en) Prosthesis for arthrodhesis
ZA201207569B (en) Implants and methods for correcting tissue defects
IL245440A0 (en) A method for activating a t-helper cell
SI2683815T1 (sl) Gensko modificirana celica in postopek za uporabo omenjene celice
IL246182A0 (en) Methods for repairing tissue damage using protease-resistant mutants of stromal cells derived from factor 1
HUE048470T2 (hu) Támaszték implantátumhoz
GB201110042D0 (en) Growth of cells
PT2670401E (pt) Métodos de utilização de inibidores de alk
IL227529A0 (en) Compounds and methods of cell transplantation
ZA201304743B (en) Method for enhancing engraftment of haematopoetics stem cells
ZA201404889B (en) Management of ethanol concentration during syngas fermentation
TWI561472B (en) Method of preparing lithium titanate
IL231623A0 (en) High density storage facility
PL394625A1 (pl) Sposób chlorowodorowania glicerolu
GB201109449D0 (en) Control of cell search procedure
GB201114752D0 (en) Cell staining process
EP2554659A4 (en) PROCESS FOR PREPARING ES CELLS
PL396508A1 (pl) Sposób otrzymywania elektrolitu cynkowego
GB2495842B (en) Improved storage method
HK1197425A (en) Methods and compositions for expanding cells and improving engraftment
PL2841564T3 (pl) Sposób oraz kompozycja z komórkami macierzystymi do podtrzymywania tkanki serca
EG27087A (en) New technique for differentiation of stem cells using non-ionized